EGFR variants are common gene alterations in lung adenocarcinoma, with an incidence of 10% to 50% based on different races.1 The central nervous system (CNS) is one of the most common metastatic sites in patients with EGFR-variant non–small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is lung adenocarcinoma.